Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04764851 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates
A Phase 1 study, sponsored by Emalex Biosciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT04764851 is a Phase 1 study that was terminated before completion, run by Emalex Biosciences. The registered enrollment target is 30 participants.
The verdict
NCT04764851, a Phase 1 study, was terminated before completion, sponsored by Emalex Biosciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in healthy subjects.
Interventions
- DRUG ecopipam HCl ~2mg/kg/day
- COMBINATION_PRODUCT Cohort 1 Probe Cocktail
- COMBINATION_PRODUCT Cohort 2 Probe Cocktail
- COMBINATION_PRODUCT Cohort 3 Probe Cocktail
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-02-18 |
| Est. Completion | 2021-05-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04764851
The ClinicalTrials.gov registry entry for NCT04764851 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emalex Biosciences, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which ecopipam HCl ~2mg/kg/day is the first listed.
NCT04764851 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04764851 about?
NCT04764851 is a clinical study titled "Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates". This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in healthy subjects.
What is the current status of trial NCT04764851?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2021-02-18. Estimated completion is 2021-05-07.
What interventions are being tested in trial NCT04764851?
The interventions under investigation include: ecopipam HCl ~2mg/kg/day (DRUG), Cohort 1 Probe Cocktail (COMBINATION_PRODUCT), Cohort 2 Probe Cocktail (COMBINATION_PRODUCT), Cohort 3 Probe Cocktail (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04764851?
This trial is sponsored by Emalex Biosciences, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.